Figure 7. LCZ696 attenuated doxorubicin-induced heart injury through the TLR2-MyD88 pathway
The mechanism by which LCZ696 relieves DOX-induced cardiac inflammation, fibrosis and heart failure lies in reducing the formation of TLR2-MyD88 complexes.